Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon’s groundless damages claim of over $200 million relating to I-Mab’s next-generation bi-specific antibody assets and awarded no damages to…
